In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional ...

Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored ...

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping ...

A new observational study finds that people with diabetes taking GLP-1 drugs have a low but doubled risk of developing neovascular age-related macular degeneration, an eye disease that can cause ...

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, ...

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of ...

A Pharmaceutical Executive article explores how specialty pharmacy programs can significantly improve outcomes for patients with rare diseases—like cystic fibrosis—by providing faster access to ...

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, ...